ADMA ADMA Biologics Inc

2.46
-0.42  -15%
Previous Close 2.88
Open 2.74
Price To Book 8.2
Market Cap 212,409,470
Shares 86,345,313
Volume 1,649,215
Short Ratio
Av. Daily Volume 2,759,223
Stock charts supplied by TradingView

NewsSee all news

  1. ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

     Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a 73% Increase Over Full Year 2018 Strengthened Balance

  2. ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing

  3. ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

    Company Offers Assistance with Coronavirus Global Health Initiatives Company Receives Notification from USPTO Regarding Extension to Its Issued Patents Related and Applied to Composition and Therapeutic Use of Immune

  4. ADMA Biologics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing

  5. ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

FDA Approval announced April 1, 2019.
ASCENIV (RI-002)
Primary Immune Deficiency Diseases
Response to Complete Response Letter submitted January 7, 2019.
BIVIGAM
Primary humoral immunodeficiency

Latest News

  1. ADMA Biologics Reports Fourth Quarter and Full Year 2019 Financial Results and Highlights Recent Company Progress

     Achieved Fourth Quarter 2019 Total Revenues of $12.0 Million, a 197% Increase Over Fourth Quarter 2018 Achieved Full Year 2019 Total Revenues of $29.3 Million, a 73% Increase Over Full Year 2018 Strengthened Balance

  2. ADMA Biologics to Report Fourth Quarter and Full Year 2019 Financial Results on March 12, 2020

    RAMSEY, N.J. and BOCA RATON, Fla., March 05, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing

  3. ADMA Biologics Highlights Expanded Intellectual Property Portfolio for Specialty Plasma Derived Immune Globulins Targeted Against Respiratory Infections

    Company Offers Assistance with Coronavirus Global Health Initiatives Company Receives Notification from USPTO Regarding Extension to Its Issued Patents Related and Applied to Composition and Therapeutic Use of Immune

  4. ADMA Biologics Announces Closing of Full Exercise of Underwriters' Option to Purchase Additional Shares in Connection with Its Public Offering of Common Stock

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 24, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA"), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing

  5. ADMA Biologics Receives BioNJ 2020 Innovator Award for ASCENIV™

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 11, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty

  6. ADMA Biologics Announces Pricing of Upsized $82.3 Million Public Offering of Common Stock

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company") an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing

  7. ADMA Biologics Announces Proposed $75 Million Public Offering of Common Stock

    RAMSEY, N.J. and BOCA RATON, Fla., Feb. 06, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company") an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing

  8. ADMA Biologics Announces Preliminary Fourth Quarter and Full Year 2019 Revenues and Provides 2020 Strategic Outlook

    Achieved Fourth Quarter 2019 Preliminary Unaudited Total Revenues of $11.9 Million, a 193% Increase Over Fourth Quarter 2018 Full Year 2019 Preliminary Unaudited Total Revenues of $29.2 Million, a 72% Increase Over Full

  9. ADMA Biologics Enters Into a Manufacturing and Supply Agreement to Produce and Sell Plasma-Derived Intermediate Fractions

    Agreement is Expected to Add $5-10 Million in Annual Revenues for 2020 and 2021, and $10-20 Million Per Year for 2022 Through 2024 RAMSEY, N.J. and BOCA RATON, Fla., Jan. 07, 2020 (GLOBE NEWSWIRE) -- ADMA Biologics,

  10. ADMA Biologics Added to NASDAQ Biotechnology Index

    RAMSEY, N.J. and BOCA RATON, Fla., Dec. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  11. ADMA Biologics to Present at Jefferies 2019 London Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 13, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  12. ADMA Biologics Reports Third Quarter 2019 Financial Results and Highlights Recent Company Progress

    Third Quarter Total Revenues of $7.2 Million, a 71% Increase Year Over Year Commercial Rollouts for Immunoglobulins (IVIG) Off to an Encouraging Start RAMSEY, N.J. and BOCA RATON, Fla., Nov. 06, 2019 (GLOBE NEWSWIRE)

  13. ADMA Biologics Announces Acceptance to the Plasma Protein Therapeutics Association

    RAMSEY, N.J. and BOCA RATON, Fla., Nov. 04, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  14. ADMA Biologics Announces Publication of an Article Describing the Manufacturing Process Optimization for its Commercial Products BIVIGAM® and ASCENIV™ in the Peer Reviewed Journal Immunotherapy

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 17, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a commercial biopharmaceutical company dedicated to manufacturing, marketing and

  15. ADMA Biologics Announces Data Presented at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 07, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  16. ADMA Biologics Announces Poster Presentation at IDWeek 2019

    RAMSEY, N.J. and BOCA RATON, Fla., Oct. 03, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  17. ADMA Biologics to Present at 2019 Cantor Global Healthcare Conference

    RAMSEY, N.J. and BOCA RATON, Fla., Sept. 23, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin

  18. ADMA Biologics Announces Commercial Relaunch and its First Commercial Sales of BIVIGAM®

    RAMSEY, N.J. and BOCA RATON, Fla., Aug. 22, 2019 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (NASDAQ:ADMA) ("ADMA" or the "Company"), a vertically integrated commercial biopharmaceutical and specialty immunoglobulin